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ABSTRACT 
Background: The most effective current therapy for hepatitis C virus (HCV) 
infection is the combination of pegylated interferon (peg-IFN) plus ribavirin 
(RBV). 
Objective: The aim of this retrospective analysis was to determine the rate 
of response to this therapy, and the factors affecting outcome, in patients with 
treatment-refractory chronic HCV genotype lb. 
Methods: The records of patients with chronic HCV infection and HCV geno- 
type lb who failed (nonresponse or relapse) previous treatment with standard 
interferon (IFN) + RBV were retrospectively analyzed for demographic data, 
virologic load, liver histology, biochemistry, treatment-related adverse ffects 
(AEs), and the effects of dose reduction during treatment with peg-IFN + RBV for 
48 weeks. Early virologic response (EVR) was defined as _2-log (copies/mL) 
decrease from baseline in serum HCV RNA concentration or the absence of 
detectable serum HCV RNA at treatment week 12. End-of-treatment response 
(ETR) was defined as the absence of detectable serum HCV RNA at treatment 
week 48. Sustained virologic response (SVR) was defined as the absence of de- 
tectable serum HCV RNA 24 weeks after treatment was discontinued. Factors 
affecting treatment outcome were determined using correlation analyses. 
Results: Data from the files of 17 patients (12 men, 5 women; mean [SD] age, 
48 [2] years) were analyzed. EVR was achieved in 7 patients; however, viral 
breakthrough occurred in 2 of these patients during the treatment period, and 
5 of these patients discontinued treatment because of severe treatment-related 
AEs (depression [1patient] and neutropenia [4]). Seven patients achieved ETR, 
but HCV infection relapsed uring the follow-up period. Three (18%) patients 
achieved SVR. Data concerning previous patterns of response to IFN + RBV ther- 
apy were available in 10 patients. Of these, 3 of 6 patients who had experienced 
relapse with the previous treatment achieved SVR with peg-IFN + RBV; neither 
of the 2 patients with nonresponse to the previous treatment achieved SVR. 
Major determinants of failure to reach SVR in these patients included previous 
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nonresponder pattern, noncompliance with the therapy, and advanced-stage 
liver fibrosis. Tolerability was similar to that with the previous treatment. 
Conclusions: In this study in patients with chronic HCV genotype lb infec- 
tion and a history of relapse or nonresponse to standard IFN + RBV treatment, 
treatment with peg-IFN + RBV achieved an SVR rate of 18%. Further research 
is needed to determine the role of peg-IFN + RBV in the re-treatment of HCV in- 
fection. (Curr Ther Res Clin Exp. 2005;66:451-462) Copyright © 2005 Excerpta 
Medica, Inc. 
Key words: hepatitis C, treatment, nonresponders, ribavirin combination, 
pegylated interferon, treatment failure, retrospective. 
INTRODUCTION 
The current optimal therapy for patients with chronic hepatitis Cvirus (HCV) infec- 
tion is the combination of pegylated interferon (peg-IFN) plus ribavirin 0~V). 
Two large, randomized, controlled trials have shown that sustained virologic re- 
sponse (SVR) rates achieved with this treatment were significantly higher compar- 
ed with those achieved with standard interferon ([FIN) + RBV. 1,2 These improved 
response rates with peg-IFN led to the question of whether patients with non- 
response to standard IFN + RBV should be treated with the newer combination. 
Based on a literature search using MEDLINE (key terms: hepatitis C, re- 
treatment, and pegylated interferon; years: 2000-2005), few published studies 
assessing the role of peg-IFN + RBV are available. However, it is generally antici- 
pated that this regimen will be shown to be more efficacious compared with 
other existing IFN-based regimens because peg-IFN-based therapies are associ- 
ated with higher SVR rates compared with standard IFN-based therapies in 
treatment-naive patients. Preliminary data 3available from an ongoing study of 
212 nonresponders to IFN monotherapy or combination IFN + RBV who were re- 
treated with peg-IFN alfa-2a 180 pg/wk plus RBV 1000 to 1200 mg/d showed that 
although 55% of patients experienced end-of-treatment response (ETR), only 
20% achieved SVR. 
Krawitt et al 4 evaluated 604 patients (73% male; mean age, 49.9 years; 77% 
white) with HCV, of whom 64% had previously been treated with IFN + RBV. The 
mean estimated uration of HCV infection was 26.5 years, 89% had HCV geno- 
type 1, 75% had serum HCV RNA concentrations >1.5 million IU/mL, and 39% 
had cirrhosis. After treatment with peg-IFN + RBV, HCV RNA was undetectable 
in 35% of patients, and 18% achieved SVR. Factors associated with the greatest 
likelihood of SVR included previous treatment with IFN monotherapy, HCV 
genotype 2 or 3, serum HCV RNA concentration <1.5 x 106 IU/mL, and the 
absence of cirrhosis. Black patients responded poorly to treatment; SVR was 
observed in only 6% of these patients. Similarly, white patients with multiple 
poor prognostic factors, including prior treatment failure with IFN + RBV, HCV 
genotype 1, serum HCV RNA concentration >1.5 x 106 IU/mL, and cirrhosis, also 
had an SVR rate of only 6%. 
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The objectives of the present retrospective study were to determine the rate 
of response to peg-IFN + RBV, and the factors affecting treatment outcome, in 
patients with chronic HCV genotype lb infection and nonresponse or relapse 
with previous standard IFN + RBV treatment. 
MATERIALS AND METHODS 
Data Collection 
From January 2002 to October 2004, 62 white patients with chronic HCV 
infection were seen in the hepatology outpatient clinic at the Department of 
Gastroenterology, Gazi University, Ankara, Turkey. Of these, data from patients 
aged ___18 years with chronic HCV genotype lb infection who had not achieved 
SVR with previous IFN + RBV therapy, and who were then given peg-IFN alfa-2a 
180 1Jg/wk combined with RBV 1000 mg/d (body weight, <75 kg) or 1200 mg/d 
(body weight, _-_75 kg), depending on body weight, for 48 weeks were included 
in this retrospective analysis. Histories were taken from the patients, available 
family members (especially regarding alcohol use), and the medical archives of 
our department. Data from patients who tested positive for serum HIV antibody 
or had other types of liver disease (eg, metabolic, vascular, toxic, viral coinfec- 
tion) were excluded. Data from patients who consumed >30 g of alcohol per day 
were also excluded. Local ethics committee approval was not required because 
the research was done using the previously recorded data. The patients pro- 
vided written informed consent prior to participation in the treatment protocol. 
Assessment of Treatment Response 
Using patient records obtained from the clinic's electronic database, which 
included regular follow-up data measured at 12, 24, 36, and 48 weeks of treat- 
ment for our research purposes, we analyzed the demographic characteristics, 
virologic load (serum HCV RNA concentration), liver histology, biochemistry, 
treatment-related a verse effects (AEs), thyroid function, and the effects of 
dose reduction. Patients were classified based on their response to previous 
treatment with standard IFN + RBV, as follows: nonresponders, relapsers, or 
treatment failures (discontinuation due to AEs). HCV RNA levels were assessed 
throughout he peg-IFN + RBV treatment period using a real-time qualitative 
polymerase chain reaction (PCR) assay (Cobas Amplicor HCV test version 2.0, 
Roche Diagnostics, Inc., Somerville, New Jersey) (detection limit, <50 IU/mL 
[100 copies/mL]) and quantified by the Cobas Amplicor HCV Monitor test ver- 
sion 2.0 (Roche Diagnostics, Inc.) (detection limit, <600 IU/mL). 5~ As recom- 
mended in the National Institutes of Health Consensus Development Con- 
ference Statement on the management of hepatitis C published in 2002, 8 
combination therapy was to be discontinued if the HCV RNA level failed to 
decrease >2 logs (copies/mL) or remained within detectable limits by quantita- 
tive PCR assay at week 12. An experienced pathologist blinded to treatment 
assignment performed the histopathologic evaluation using liver biopsy data 
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from the previous treatment period. All biopsy specimens were assigned a 
Histologic Activity Index 9 (HAl) inf lammatory score (scale: 0 = no periportal 
bridging or necrosis and portal inflammation to 18 = multilobular necrosis, 
marked [involvement of >2/3 lobules or nodules] intralobular degeneration, and 
focal necrosis) and a fibrosis score (scale: 0 = none to 4 = cirrhosis) based on 
criteria from Ishak et al)  ° The dose was to be reduced if the patient had an 
absolute neutrophil  count <1 × 103 cells/mL, platelet count <50 x 103 cells/mL, 
or a hemoglobin concentrat ion <10 g/dL. If the laboratory AEs persisted after 
dose reduction, treatment was to be discontinued. Furthermore, treatment was 
to be discontinued if the patient developed severe depression (major depres- 
sive episode based on criteria defined in the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition 11) despite antidepressant medication during 
the treatment period. Treatment compliance was assessed using counts of 
empty pill boxes and syringes at each study visit. 
Response to treatment was classified as follows. Virologic response was 
defined as the absence of detectable serum HCV RNA at 24 weeks after starting 
treatment. Early virologic response (EVR) was defined as >_2-log (copies/mL) 
decrease from baseline in serum HCV RNA concentrat ion or the absence of 
detectable serum HCV RNA at treatment week 12. Viral breakthrough was de- 
fined as the reappearance of HCV RNA during continuous therapy after pre- 
vious response. ETR was defined as the absence of detectable serum HCV RNA 
at treatment week 48. SVR (pr imary end point) was defined as the absence of 
detectable serum HCV RNA 24 weeks after treatment was discontinued. 
Statistical Analysis 
Correlation analyses to determine factors affecting treatment outcome were 
performed using the Spearman correlation analysis. Statistical analyses were 
performed using SPSS version 9.0 (SPSS Inc., Chicago, Illinois). P < 0.05 was con- 
sidered statistically significant. 
RESULTS 
Study Population 
Seventeen patients (12 men, 5 women; mean [SD] age, 48 [2] years) were 
included in the study (Table I). Two patients were nonresponders and 6 pa- 
tients were relapsers with previous treatment. Two patients were considered 
treatment failures with standard IFN + RBV due to premature discontinuation as 
a result of AEs. Data concerning previous patterns of response were lacking in 
7 patients. However, based on the fact that these patients were still HCV- 
RNA-positive after IFN + RBV treatment, hey were considered nonresponders 
or treatment failures (Table !I). Based on liver biopsy data from the previous 
treatment period, 14 patients underwent liver biopsy before treatment with 
peg-IFN + RBV; the remaining 3 did not (1 patient had undergone a liver biopsy 
within the previous 12 months, and 2 were unwilling to undergo the procedure).  
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Table I. Baseline demographic and clinical characteristics of the 
study patients (N = 17). 
Characteristic Value 
Age, y 
Mean (SD) 
Range 
Race 
White 
Sex~ no. 
Male 
Female 
Estimated duration of infection, y 
Mean (SD) 
Range 
Weight, kg 
Mean (SD) 
Range 
Body mass index, kg/m 2 
Mean (SD) 
Range 
Liver enzymes 
ALT, mean (SD), x ULN 
Mean (SD) 
Range 
AST/ALT ratio 
Mean (SD) 
Range 
HCV RNA, copies/mL 
Serum concentration 
Mean (SD) 
Range 
Loglo serum concentration 
Mean (SD) 
Range 
HAl* 
Median (SE) 
Range 
Fibrosis stage t
Mean (SD) 
Range 
48 (2) 
29-60 
17 
12 
5 
7.8 (5.6) 
1-15 
79.6 (16.3) 
65-96 
28.1 (6.6) 
20-34 
2.16 (0.98) 
0.52-5.60 
0.87 (0.54) 
0.42-2.55 
5.5 x 106 (4.3 x 106) 
5 .0x10 s to2 .4x  108 
5.4(2.1) 
5.0-8.0 
6 (0.9) 
1-14 
2 (0.2) 
1-4 
(continued) 
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Table I. (Continued) 
Characteristic Value 
Cytology, cells x 103/mL 
Leukocytes 
Mean (SD) 5.2 (1.52) 
Range 3.8-9.6 
Neutrophils 
Mean (SD) 3.2 (1.1) 
Range 1.9-4.6 
Platelets 
Mean (SD) 175.0 (60.6) 
Range 110-545 
Hb concentration, g/dL 
Mean (SD) 16.3 (4.4) 
Range 10.7-19.5 
ALT -- alanine aminotransferase; ULN = upper limit of normal; AST -- aspartate 
aminotransferase; HCV = hepatitis C virus; HAl = histologic activity index; Hb = 
hemoglobin. 
*HAl scale: 0 = no periportal bridging or necrosis, portal inflammation to 18 = 
multilobular necrosis, marked (involvement of >2/3 Iobules or nodules) intralob- 
ular degeneration and focal necrosis. 9
tFibrosis scale: 0 = none to 4 = cirrhosis. 
Table II. Previous patterns of response to treatment with standard interferon (IFN) 
plus ribavirin (RBV) and current patterns of response to treatment with 
pegylated IFN + RBV in the study group (N = 17). 
Previous Pattern of Response Current Pattern of Response 
Relapse (6/1 7 patients) SVR (3/6 patients) 
ETR (3/6 patients) 
Viral breakthrough (2/2 patients) 
Discontinued due to >_1 AE (2/2 patients) 
ETR (4/7 patients) 
Discontinued due to ___1 AE (3/7 patients) 
Nonresponse (2/1 7 patients) 
Discontinued due to >-1 AE (2/1 7 patients) 
NA* (7/1 7 patients) 
SVR -- sustained virologic response; ETR = end-of-treatment response; AE = adverse effect. 
*Detailed data regarding the pattern of response was not available in these patients. 
456 
M. Cindoruk et aL 
Treatment Response 
Rates of virologic response to treatment with peg-IFN alfa-2a + RBV are sum- 
marized in Table II. Two patients achieved EVR but experienced viral break- 
through during the treatment period. Seven patients achieved ETR; however, 
their HCV infection relapsed during the follow-up period. Five additional pa- 
tients achieved EVR, and 3 achieved SVR. 
Detailed analysis revealed that the 2 patients who had viral breakthrough 
were both nonresponders to previous therapy. We were able to obtain the 
details of previous treatment data in 3 of 7 patients who achieved ETR. These 
patients all had the same pattern of response to standard IFN + RBV therapy: 
they responded to the treatment but relapsed at some point after 12 weeks. 
The 5 patients who achieved EVR (measured at week 12) discontinued treat- 
ment due to severe drug-related AEs. One of these patients developed epression 
during the first 24 weeks of treatment. In this patient, antidepressant therapy with 
a selective serotonin reuptake inhibitor was started, and the dose of peg-IFN was 
reduced to 135 pg/wk and then to 90 pg/wk in a stepwise manner. Although this 
patient's erum HCV RNA was undetectahle, symptoms of depression worsened, 
and treatment with peg-IFN + RBV was discontinued. Hematologic AEs, mainly neu- 
tropenia (neutrophil count, <1000 cells/mL), developed inthe other 4 patients, and 
mild thrombocytopenia developed in2 patients. Although the peg-IFN dosage was 
decreased to 90 pg/wk in these 4 patients, neutropenia persisted, and treatment 
was discontinued in the first 24 weeks. In 2 of these 4 patients, liver histology re- 
vealed stage 4 fibrosis. These 2 patients had severe neutropenia n their previous 
treatment with IFN + RBV, and that treatment was discontinued prematurely. 
All 3 of the patients who achieved SVR were previous relapsers. These pa- 
tients experienced mild treatment-related AEs (flulike symptoms, arthralgia). 
All of them had EVR in week 12. 
Factors Affecting Treatment Outcome 
The factors affecting the outcome of peg-IFN + RBV therapy are shown in 
Table III. The main factors in the failure to achieve SVR were advanced-stage 
liver fibrosis, nonresponse to prior therapy, and noncompliance with therapy 
(all, P< 0.01); prior relapse was also a factor in failure to achieve SVR (P< 0.05). 
No significant correlation was found between age, sex, viral load, or degree 
of liver inflammation and current response pattern. However, prior relapse was 
significantly correlated with achieving SVR (P < 0.05; r = 0.950). Severe AEs lead- 
ing to discontinuation f therapy were correlated with stage 4 fibrosis (P < 0.01; 
r -- 0.513). There was a positive correlation between the HAl score and the log 
value of the viral load (P < 0.01; r = 0.573). 
DISCUSSION 
The currently accepted primary end point of HCV therapy is SVR. With the com- 
bination of peg-IFN + RBV, an SVR rate of 40% to 45% can be achieved in patients 
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Table III. Comparison of demographic, histologic, virologic, and therapy-related fea- 
tures of patients with or wi thout  sustained virologic response (SVR) to 
pegylated interferon plus ribavirin. 
SVR Non-SVR 
Factors Influencing Treatment Success (n = 3) (n = 14) 
Age, mean (SD), y 45 
Weight, mean (SD), kg 81.4 
BMI, mean (SD), kg/m 2 27.6 
ALl-, mean (SD), x ULN 2.15 
HCV RNA 
Serum concentration, mean, copies/mL 7.9 x 106 
Log10 serum HCV RNA concentration, mean (SD) 5.1 (2.5) 
HAl, median (SE)* 5 (1.6) 
Fibrosis stage, median (SE) t 1 (0.5) 
Previous pattern of response to therapy, no.§ 3 
Relapse 3 
Nonresponse 0 
Noncompliance 0 
(4) 47 (2) 
(I 2.5) 77.3 (I 1.4) 
(4.5) 29,1 (5.2) 
(I .I O) 2.19 (0.96) 
5.1 ×106 
5.4 (1.5) 
6 (o.5) 
3 (1.5)~ 
7 
311 
2~ 
2~ 
BMI = body mass index; ALT -- alanine aminotransferase; ULN = upper limit of normal; HCV = 
hepatitis C virus; HAl = histologic activity index. 
*HAl scale: 0 = no periportal bridging or necrosis and portal inflammation to 18 = multilobular necrosis, 
marked (involvement of >2/3 Iobules or nodules) intralobular degeneration, and focal necrosis. 9
tFibrosis scale: 0 = none to 4 = cirrhosis. 
~P < 0.01 versus SVR. 
§Patients in whom previous response patterns were available. 
II p < 0.05 versus SVR. 
with HCV genotype 1 and ~80% of patients with genotype 2 or 3 infection] ,2
Especially for patients with genotype 1infection, these results are significantly 
improved compared with those of treatment with standard IFN + RBV] 2 As a 
result, the patients who were nonresponders to the previous therapies are now 
considered candidates for treatment with peg-lFN + RBV. 12 
Considerable data are available regarding treatment of HCV infection in non- 
responders to previous tandard IFN therapies] 3-17 In these trials, the addition 
of amantadine or thymosin ~1 slightly increased the SVR rate; however, contro- 
versies exist. 13-17 These studies were mainly performed in nonresponders. A 
pilot study revealed an increased benefit with prolonged IFN treatment] 8,19 
Trials of intensive or induction therapies with daily or higher doses had con- 
flicting results. 2°,21 Experimental therapies, including interleukin (IL)-12 and 
IL-2, failed to achieve sufficient herapeutic success. 22,23 Consensus IFN (ie, IFN 
alfacon-1, a recombinant, synthetic type 1 IFN) has been reported to be a suc- 
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cessful therapy for standard IFN failures; however, this drug is not available in 
many countries. 24-27 
Although few published trials evaluating the role of peg-IFN + RBV in IFN non- 
responders or relapsers are available, it is thought hat SVR rates might be 
improved with this treatment. Preliminary data from the Hepatitis C Antiviral 
Long-Term Treatment against Cirrhosis (HALT-C) trial 3 were published in 2002. 
In that study, 212 nonresponders to prior IFN monotherapy or combination 
therapy were treated with peg-IFN alfa-2a 180 1Jg/wk plus RBV 1000 to 1200 mg/d. 
Although 55% of patients achieved ETR, only 20% achieved SVR. Factors posi- 
tively correlated with achieving SVR were previous relapse, non-lb genotype, 
and IFN monotherapy nonresponse. 
The pattern of response to prior therapy seems to have a strong influence on 
the rates of response to subsequent treatment, as shown in a report of the 
HALT-C triaP 2 published in 2004, in which only nonresponders were enrolled. 
The SVR rate was 18% at 48 weeks. In a separate study, the SVR rate in relapsers 
was 32% to 50%. 28 In another study, the ETR rates at 24 weeks were 71% to 76% 
in prior relapsers and 26% to 52% in prior nonresponders. 29 These data suggest 
a better outcome in prior relapsers compared with prior nonresponders when 
HCV infection was treated with peg-IFN + RBV. 
In the present study, all of the patients who achieved an SVR were prior 
relapsers. Prior nonresponders and patients with premature treatment discon- 
tinuation due to AEs failed to achieve SVR. Based on previous work, 2,3° patients 
who achieved EVR, defined as __2 log (100-fold) decline in the serum level of 
HCV RNA or no detectable HCV RNA within the first 12 weeks of treatment, had 
a higher ate of SVR. IFN susceptibility ofHCV was found to be a major factor in 
treatment outcome. EVR is the most valuable prognostic factor in HCV treat- 
ment. For this reason, nonresponders who failed to achieve EVR with standard 
1FN + RBV probably will not respond to the newer peg-IFN + RBV combination. 
Adherence to therapy has been identified as an important determinant of
SVR. 31 Noncompliance is sometimes defined as a dose reduction to >80% of 
the original dose, or treatment discontinuation before 80% of the planned 
duration of therapy has been completed. 2,32-34 In the patients in the present 
study, AE-related noncompliance occurred in 5 patients (depression [1patient], 
neutropenia [4]). Two of these patients had the same AEs with the previous 
treatment. None of the patients required a reduction in RBV dose. The main 
toxicity was neutropenia, which is a common AE of IFN treatment. However, 
these findings are contrary to the findings reported by Davis et al. 3° In that 
study, reducing the RBV dose but not the peg-IFN dose in the first 12 weeks 
was associated with a significant decrease in the virologic response rate. 
Moreover, reducing the dose of peg-IFN alfa-2a within the first 20 weeks of 
treatment did not appear to affect the virologic response at week 20 or the 
SVR rate. After 20 weeks, neither IFN nor RBV dose reduction affected viro- 
logic response. For this reason, the potential role of adjuvant hematologic 
growth factors is being studied. 33 
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There were limitations of the present study, including its small sample size, 
retrospect ive design, and lack of data concerning previous pattern of response 
in 7 patients. 
CONCLUSIONS 
In this study in patients with chronic HCV genotype lb infection and a his- 
tory  of relapse or nonresponse to standard IFN + RBV treatment, reatment with 
peg-IFN + RBV achieved an SVR rate of 18%. Major determinants of failure to 
reach SVR in these patients included advanced-stage liver fibrosis, previous 
nonresponse pattern, and noncompliance with the therapy. Further research is 
needed to determine the role of peg-IFN + RBV in the re-treatment of HCV infection. 
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